Does the media favor RZLT or SNDX?

In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Rezolute. MarketBeat recorded 3 mentions for Syndax Pharmaceuticals and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.39 beat Syndax Pharmaceuticals' score of 1.02 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, RZLT or IMCR?

Immunocore has higher revenue and earnings than Rezolute. Immunocore is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Immunocore $400.02M 4.69 -$35.51M -$0.37 N/A

Is RZLT or IMCR more profitable?

Rezolute has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Immunocore -4.20% -4.54% -1.66%

Does the media refer more to RZLT or IMCR?

In the previous week, Immunocore had 1 more articles in the media than Rezolute. MarketBeat recorded 3 mentions for Immunocore and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.39 beat Immunocore's score of 0.28 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, RZLT or XNCR?

Rezolute has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A Xencor $125.58M 16.46 -$91.92M -$2.17 N/A

Is RZLT or XNCR more profitable?

Rezolute has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% Xencor -155.59% -28.66% -20.38%

Does the media favor RZLT or XNCR?

In the previous week, Rezolute and Rezolute both had 2 articles in the media. Rezolute's average media sentiment score of 1.39 beat Xencor's score of 1.04 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, RZLT or ANAB?

AnaptysBio has higher revenue and earnings than Rezolute. AnaptysBio is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$74.41M -$0.82 N/A AnaptysBio $234.60M 7.29 -$13.23M -$1.08 N/A

Is RZLT or ANAB more profitable?

Rezolute has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -58.82% -54.48% AnaptysBio -11.53% N/A -7.75%

Does the media prefer RZLT or ANAB?

In the previous week, Rezolute and Rezolute both had 2 articles in the media. Rezolute's average media sentiment score of 1.39 beat AnaptysBio's score of 1.12 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RZLT or RXRX?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Rezolute. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.39 beat Recursion Pharmaceuticals' score of 0.69 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rezolute (RZLT) Competitors

$5.09 +0.43 (+9.23%)

As of 08/21/2026 04:00 PM Eastern

Compare

RZLT vs. SNDX, IMCR, XNCR, ANAB, and RXRX

Should you buy Rezolute stock or one of its competitors? Rezolute's main competitors and comparable companies include Syndax Pharmaceuticals (SNDX), Immunocore (IMCR), Xencor (XNCR), AnaptysBio (ANAB), and Recursion Pharmaceuticals (RXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rezolute compare to Syndax Pharmaceuticals?

Rezolute (NASDAQ:RZLT) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Rezolute has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Rezolute's return on equity of -58.82% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Rezolute has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rezolute presently has a consensus price target of $9.38, indicating a potential upside of 84.18%. Syndax Pharmaceuticals has a consensus price target of $41.55, indicating a potential upside of 111.43%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Rezolute has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Syndax Pharmaceuticals	$252.25M	6.90	-$285.42M	-$2.51	N/A

In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Rezolute. MarketBeat recorded 3 mentions for Syndax Pharmaceuticals and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.39 beat Syndax Pharmaceuticals' score of 1.02 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rezolute beats Syndax Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to Immunocore?

Rezolute (NASDAQ:RZLT) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

83.0% of Rezolute shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Comparatively, 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Rezolute has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Immunocore	-4.20%	-4.54%	-1.66%

Rezolute has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Rezolute currently has a consensus target price of $9.38, indicating a potential upside of 84.18%. Immunocore has a consensus target price of $56.38, indicating a potential upside of 52.86%. Given Rezolute's higher probable upside, analysts clearly believe Rezolute is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Immunocore had 1 more articles in the media than Rezolute. MarketBeat recorded 3 mentions for Immunocore and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.39 beat Immunocore's score of 0.28 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore has higher revenue and earnings than Rezolute. Immunocore is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Immunocore	$400.02M	4.69	-$35.51M	-$0.37	N/A

Summary

Immunocore beats Rezolute on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to Xencor?

Rezolute (NASDAQ:RZLT) and Xencor (NASDAQ:XNCR) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Rezolute has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Xencor has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

In the previous week, Rezolute and Rezolute both had 2 articles in the media. Rezolute's average media sentiment score of 1.39 beat Xencor's score of 1.04 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.0% of Rezolute shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Comparatively, 5.1% of Xencor shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rezolute has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Xencor	-155.59%	-28.66%	-20.38%

Rezolute presently has a consensus price target of $9.38, indicating a potential upside of 84.18%. Xencor has a consensus price target of $24.86, indicating a potential downside of 10.59%. Given Rezolute's stronger consensus rating and higher possible upside, equities analysts plainly believe Rezolute is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Rezolute has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Xencor	$125.58M	16.46	-$91.92M	-$2.17	N/A

Summary

Rezolute beats Xencor on 10 of the 14 factors compared between the two stocks.

How does Rezolute compare to AnaptysBio?

Rezolute (NASDAQ:RZLT) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Rezolute presently has a consensus price target of $9.38, suggesting a potential upside of 84.18%. AnaptysBio has a consensus price target of $82.00, suggesting a potential upside of 42.02%. Given Rezolute's higher possible upside, analysts plainly believe Rezolute is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rezolute has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

In the previous week, Rezolute and Rezolute both had 2 articles in the media. Rezolute's average media sentiment score of 1.39 beat AnaptysBio's score of 1.12 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has higher revenue and earnings than Rezolute. AnaptysBio is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
AnaptysBio	$234.60M	7.29	-$13.23M	-$1.08	N/A

Rezolute has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
AnaptysBio	-11.53%	N/A	-7.75%

Summary

AnaptysBio beats Rezolute on 8 of the 14 factors compared between the two stocks.

How does Rezolute compare to Recursion Pharmaceuticals?

Rezolute (NASDAQ:RZLT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Rezolute has higher earnings, but lower revenue than Recursion Pharmaceuticals. Rezolute is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A
Recursion Pharmaceuticals	$74.68M	25.09	-$644.76M	-$1.04	N/A

Rezolute has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-58.82%	-54.48%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Rezolute. MarketBeat recorded 4 mentions for Recursion Pharmaceuticals and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.39 beat Recursion Pharmaceuticals' score of 0.69 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rezolute has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Rezolute currently has a consensus target price of $9.38, indicating a potential upside of 84.18%. Recursion Pharmaceuticals has a consensus target price of $8.06, indicating a potential upside of 130.29%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Recursion Pharmaceuticals beats Rezolute on 8 of the 15 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RZLT vs. The Competition

Export

Metric	Rezolute	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$490.13M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-6.21	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	2.74	16.80	13.05	6.20
Net Income	-$74.41M	-$12.50M	$3.47B	$348.59M
7 Day Performance	10.65%	3.29%	2.09%	0.08%
1 Month Performance	-4.14%	8.23%	6.64%	3.88%
1 Year Performance	-27.29%	55.05%	25.02%	16.98%

Rezolute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RZLT Rezolute	2.9911 of 5 stars	$5.09 +9.2%	$9.38 +84.2%	-27.3%	$490.13M	N/A	N/A	40	Positive News High Trading Volume
SNDX Syndax Pharmaceuticals	2.7464 of 5 stars	$19.76 -0.4%	$41.91 +112.1%	+21.0%	$1.76B	$172.35M	N/A	110	Analyst Forecast
IMCR Immunocore	3.6744 of 5 stars	$35.05 +2.5%	$57.29 +63.4%	+12.0%	$1.74B	$400.02M	N/A	320	Analyst Forecast
XNCR Xencor	1.1605 of 5 stars	$23.12 -0.9%	$24.86 +7.5%	+230.6%	$1.74B	$104.97M	N/A	280	Positive News
ANAB AnaptysBio	2.5559 of 5 stars	$59.69 +2.1%	$82.00 +37.4%	+185.6%	$1.73B	$234.60M	N/A	100	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RZLT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rezolute (RZLT) Competitors

RZLT vs. SNDX, IMCR, XNCR, ANAB, and RXRX

How does Rezolute compare to Syndax Pharmaceuticals?

Summary

How does Rezolute compare to Immunocore?

Summary

How does Rezolute compare to Xencor?

Summary

How does Rezolute compare to AnaptysBio?

Summary

How does Rezolute compare to Recursion Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rezolute (RZLT) Competitors

RZLT vs. SNDX, IMCR, XNCR, ANAB, and RXRX

How does Rezolute compare to Syndax Pharmaceuticals?

Is RZLT or SNDX more profitable?

Which has more risk & volatility, RZLT or SNDX?

Do institutionals and insiders believe in RZLT or SNDX?

Do analysts prefer RZLT or SNDX?

Which has higher valuation & earnings, RZLT or SNDX?

Does the media favor RZLT or SNDX?

Summary

How does Rezolute compare to Immunocore?

Do insiders and institutionals believe in RZLT or IMCR?

Is RZLT or IMCR more profitable?

Which has more volatility & risk, RZLT or IMCR?

Do analysts prefer RZLT or IMCR?

Does the media refer more to RZLT or IMCR?

Which has preferable earnings and valuation, RZLT or IMCR?

Summary

How does Rezolute compare to Xencor?

Which has more risk and volatility, RZLT or XNCR?

Does the media favor RZLT or XNCR?

Do insiders and institutionals believe in RZLT or XNCR?

Is RZLT or XNCR more profitable?

Do analysts recommend RZLT or XNCR?

Which has better earnings and valuation, RZLT or XNCR?

Summary

How does Rezolute compare to AnaptysBio?

Do analysts recommend RZLT or ANAB?

Do insiders & institutionals have more ownership in RZLT or ANAB?

Which has more volatility & risk, RZLT or ANAB?

Does the media prefer RZLT or ANAB?

Which has better valuation & earnings, RZLT or ANAB?

Is RZLT or ANAB more profitable?

Summary

How does Rezolute compare to Recursion Pharmaceuticals?

Which has preferable valuation and earnings, RZLT or RXRX?

Is RZLT or RXRX more profitable?

Does the media favor RZLT or RXRX?

Which has more risk & volatility, RZLT or RXRX?

Do analysts rate RZLT or RXRX?

Do insiders and institutionals believe in RZLT or RXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools